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Abstract
Hepatitis E virus nanoparticle (HEVNP) is an orally stable, mucosa-penetrating 
delivery platform for noninvasive, targeted delivery of therapeutic and diagnostic 
agents. HEVNP does not carry HEV genomic RNA and is incapable of replication. 
The key characteristics that make HEVNP an ideal and unique vehicle for diagnostic 
and therapeutic delivery include surface plasticity, resistance to the harsh environ-
ment of the gastrointestinal (GI) tract, significant payload capacity, platform 
sustainability, and safety. Furthermore, HEVNP is easily produced using currently 
available expression/purification technologies; can be easily formulated as a 
liquid, powder, or solid; and can be distributed (and stored) without the need for a 
temperature-controlled supply chain.
Keywords: hepatitis E virus, HEV, nanoparticle, HEVNP, noninvasive vaccine, 
mucosal delivery, cryo-EM
1. Introduction
1.1 Noninvasive vaccine delivery by nanocarriers
Currently, most vaccines, drugs, and diagnostic/therapeutic agents are admin-
istered through invasive routes such as injection. There has been vast interest in 
the development of noninvasive, targeted, stable, and convenient drug delivery 
platforms that obviate the drawbacks of invasive delivery methods (reviewed in 
[1–6]). Systemic drug delivery through noninvasive routes requires that the delivery 
platform protects the drug compound while it traverses physiological barriers. 
Noninvasive delivery platforms, as in the case of traditional delivery platforms, 
should also distribute the drug effectively and selectively so that only the targeted 
cells receive the therapeutic agent. The rapid evolution of nanotechnology has 
shed light on the huge potential of nanocarrier platforms for targeting and drug 
delivery. Recent developments in the optimization of drug nanocarriers in terms of 
packaging, delivery, and targeting have the potential to revolutionize noninvasive 
administration and delivery of therapeutics and diagnostics through the mucosa. 
Several nanocarrier systems have been developed that take advantage of these 
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developments and additionally show diminished toxicity in nontargeted cells and 
tissues. Despite these early successes, instability under physiological conditions, 
inefficient targeting, toxicity, and lack of bioavailability impose serious limitations 
for the development of an effective mucosal delivery platform.
While there are several routes of mucosal drug delivery, the oral and nasal routes 
are among the most safe and preferred by patients. The inherent characteristics of 
a nanocarrier such as structural composition, size, and natural stability play major 
roles in the potential success of a drug delivery system (reviewed in [1–4, 7–9]). 
For many nanocarrier platforms, problems with enzymatic degradation, limited 
penetration of the thick mucosal layer, and subsequently transportation of drugs 
through transcellular or paracellular routes are major shortcomings. The major-
ity of currently available nanocarriers consist of simple structures that are on the 
nanometer to micrometer scale. Theranostic delivery vehicles that are currently 
used or considered for use fall into a handful of categories including polymers, 
lipids, solid-lipid carriers, gold carriers, nanotubes, immunostimulant complexes, 
magnetic carriers, and virus-like particles (VLPs)  
[3, 8, 9]. The size and exact composition of these nanocarriers are commonly 
altered and optimized based on their intended application. The key factors required 
for entry and distribution of theranostics include high degrees of bioavailability, 
the ability to withstand physiological conditions without degradation or premature 
exposure of the drug, and efficient distribution by overcoming the physical and 
enzymatic barriers through noninvasive routes.
1.2 Nanocarrier platform based on viral capsids
Evolutionarily, viruses adapt and coevolve with their host. Genetic engineering 
techniques and elucidation of viral structures have enabled virologist to generate 
empty capsids, called VLPs, which retain the physical characteristics of the capsid 
structure but lack the viral genome. VLPs thus exhibit the structural characteristics of 
the authentic virus but are incapable of replicating. In addition to being noninfectious, 
VLPs are generally nontoxic, biodegradable, and highly biocompatible. Structurally, 
the symmetrical configuration of VLPs allows them to be developed as nanocarrier 
systems that can entrap not only foreign nucleic acids but also peptides and imaging 
agents within their internal cavity. The exterior surface of VLPs, in some cases, can 
be tagged with targeting ligands without disruption of the VLP structure. The VLP 
assembles spontaneously and forms highly ordered structures following recombinant 
expression of the capsid protein (CP) in prokaryotic, eukaryotic, and cell-free protein 
expression systems. Currently, there are numerous ongoing VLP-based clinical trials 
worldwide [10–13]. From these clinical trials, a handful of VLP-based vaccines have 
been approved by the US FDA and other governmental regulatory agencies. For 
example, VLPs of hepatitis B virus (HBV), human papillomavirus (HPV), influenza 
virus, human parvovirus, and Norwalk virus have shown success in clinical trials or 
have been commercially developed as vaccines. The effectiveness of the delivery of 
therapeutic and/or diagnostic payloads using VLPs, as well as VLP surface modulation 
by attachment of ligands and tracking molecules, has been recently reviewed [10, 
11, 14]. Here, a description of the key advantages and application of hepatitis E virus 
nanoparticles for use in vaccine development will be discussed.
2. Structure of hepatitis E virus capsid and HEVNP
Significant effort has been invested in characterizing the structure of the 
capsid of HEV by biochemical methods, imaging (X-ray crystallography and 
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cryogenic electron microscopy (cryo-EM)), and molecular biological techniques 
[15–22]. These studies have revealed the underlying architecture and biochemical 
composition of HEV (reviewed in [1, 2, 23, 24]). The authentic HEV is composed 
of 180 monomers of capsid protein (CP) that are assembled into an icosahedral 
cage in an RNA-dependent manner with a triangulation number of 3 (T = 3). 
Native HEV has a virion diameter of approximately 45 nm. When the native CP is 
truncated (leaving amino acid (aa) residues 112–608), this truncated CP forms a 
smaller particle with a diameter of approximately 27 nm. This structure, known 
as the HEV nanoparticle (HEVNP), is composed of 60 monomers (i.e., 30 CP 
dimers) of the truncated CP and forms a T = 1 icosahedral conformation. The CP 
is comprised of three domains: S (shell domain, aa 118–317), M (middle domain, 
aa 318–451), and P (protrusion domain, aa 452–606) (Figure 1). The S domain is 
the most conserved region among HEV genotypes and, along with the M domain, 
is responsible for the formation of the HEV capsid base [17, 19, 25]. The P domain, 
as the name suggests, protrudes from the capsid surface and plays a role in CP 
dimerization [18, 26], HEV capsid antigenicity [19, 27, 28], and recognition by 
the host cell receptor [29]. The M domain interacts strongly with the P domain 
through a long proline-rich hinge; however, the biological roles of the S, M, and 
P domains are independent [19, 22, 25]. This modular functionality allows the 
P domain to be genetically modified while (i) causing no or minimal effects on 
capsid formation and (ii) retaining capsid stability and resistance to acidic and 
proteolytic conditions found in the mammalian GI tract. Additionally, genetic 
modification of the P domain results in invisibility of the capsid to host immune 
surveillance as will be discussed below. Since the P domain of HEVNP is repeated 
Figure 1. 
Modular composition of HEVNP. HEVNP is formed by 30 homodimers of the HEVNP monomer. The dimer 
is the building block of HEVNP. The HEVNP monomer is composed of three domains: Shell (S), middle (M), 
and protrusion (P). The P domain has four surface-exposed loops (L1–L4) and a C-terminus that can be 
genetically or chemically (e.G., at N573C) modified in order to functionalize the HEVNP surface.
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60 times on the surface of the capsid, it provides high accessibility for surface 
modulations that may include targeting ligands, imaging molecules, tracking 
molecules, and immunogenic peptides.
3. Advantages of waterborne HEVNP for vaccine development
As mentioned above, 30 dimers of the truncated CP of HEV will spontane-
ously self-assemble into HEVNP following heterologous expression in insect cells 
or bacteria. Unlike HEV, HEVNP does not encapsulate genomic RNA and is, thus, 
incapable of replication. HEVNP is, however, capable of encapsulating foreign RNA 
or DNA. As a vaccine delivery vehicle, HEVNP possesses a combination of advanta-
geous characteristics including surface plasticity, stability within the harsh condi-
tions of the GI tract, significant payload capacity, and platform sustainability.
3.1 Surface plasticity
The utility of the HEVNP as a mucosa-penetrating vaccine delivery platform was 
successful demonstrated by the development of an orally administered HEVNP-
based HIV vaccine [21]. In this groundbreaking study, a 15-amino-acid-long pep-
tide from the V3 loop of HIV-1 gp120 (called P18) was genetically inserted on the 
surface of HEVNP, generating the HEVNP-P18 construct (also known as 18-VLP). 
This insertion was successfully made after residue Y485 of the truncated CP, a loca-
tion that is within the antibody-binding site of HEVNP. Cryo-EM studies revealed 
that the HEVNP capsid maintained its icosahedral shape and was not disrupted 
by the P18 insertion. The successful insertion after Y485 resulted in fully formed, 
stable HEVNP. In contrast, attempts of insertion after aa residues A179, R366, A507, 
and R542 all failed to achieve the quaternary assembly of HEVNP. Clearly, surface 
modification of HEVNP via modulation at Y485 by peptide insertion does not 
interfere with capsid stability or the formation of T = 1 icosahedral organization.
Following the successful insertion of P18 after Y485, four additional aa residues 
(T489, S533, N573, and T586) have been identified as targets for modulating the 
surface of HEVNP [30]. These sites are found within four surface-accessible loops 
(L1, aa 483–491; L2, aa 530–535; L3, aa 554–561; and L4, aa 582–593) that are found 
on the P domain (Figure 1). These sites (as well as Y485) were identified based on (i) 
their three-dimensional localization on the surface of HEVNP and (ii) the likelihood 
that mutation would result in minimal or no distortion of the HEVNP structure. In 
order to test the hypotheses generated by the structural analyses regarding these sites, 
site-directed mutagenesis was performed in order to replace these residues with a 
cysteine residue. All of the cysteine mutation constructs successfully assembled into 
stable icosahedral capsids and were subjected to surface modulation through covalent 
chemical conjugation. The conjugations were performed via a cysteine acylation 
reaction with maleimide-linked biotin, and the conjugation efficiency at each site 
was determined using labeled streptavidin. Of the mutations that were generated 
(HEVNP-485C, HEVNP-489C, HEVNP-533C, HEVNP-573C, and HEVNP-586C), the 
HEVNP-573C construct showed the greatest streptavidin signal. This indicated that 
the N573C mutation of HEVNP-573C is the most surface-visible site for modulation. 
More recent structural analysis has identified additional aa residues that are found on 
the P domain (aa residues 510–514 and 520–525) as well as the M domain (residues 
342–344 and 402–408) that may be utilized as conjugation sites in a future study.
In order to demonstrate the functionality of the HEVNP-573C construct, a breast 
cancer cell-targeting ligand LXY30 [31] was chemically conjugated to HEVNP-573C 
in order to generate HEVNP-573C-LXY30 [30]. The HEVNP-573C-LXY30 construct 
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selectively binds to cells in the breast cancer cell line MDA-MB-231 (Figure 2A). 
Furthermore, in vivo fluorescence microscopy demonstrates that HEVNP-573C-
LYX30, unlike HEVNP-573C, is selectively delivered to breast cancer tumors (formed 
following the subcutaneous injection of MDA-MB-231 cells in female SPF BLAB/c 
mice) (Figure 2B). These findings demonstrate that HEVNP can be engineered for 
surface modulation by covalent attachment of a small molecule while maintaining the 
integrity of the capsid structure. HEVNP thus presents a unique platform for surface 
functionalization.
3.2 Gastrointestinal tract stability
The human GI tract is divided into the upper tract and lower tract with the upper 
tract consisting of the mouth, pharynx, esophagus, stomach, and first part of the 
small intestine (i.e., the duodenum) and the lower tract consisting of the remainder 
of the small intestine (i.e., jejunum and ileum) and large intestine [32]. Although 
the duodenum is the shortest portion of the small intestine, it is connected to and/
Figure 2. 
Selective binding and internalization of LXY30-tagged HEVNP. Breast cancer cells (MDA-MB-231) were 
inoculated with Cy5.5-labeled HEVNP (row H) or Cy5.5-labeled HEVNP tagged with LXY30 (row LXY). 
At 1 h post inoculation, the cells were visualized for nuclear dsDNA (DAPI) or Cy5.5. Cy5.5 staining is 
significantly higher in the cytoplasm of cells inoculated with HEVNP tagged with LXY30 (A). Female SPF 
BALB/c mice were injected with MDA-MB-231 cells (5 x 105). Following the formation of tumors (white 
arrows), 0.1 nmoles of Cy5.5-labeled HEVNP (row H) or Cy5.5-labeled HEVNP tagged with LXY30 (row 
LXY) was injected into the tail vein. Optical imaging of live mice at 1, 6, 24, and 48 h post injection (p.i.) 
showed that LXY30-tagged HEVNP selectively binds to the tumor at 1 h p.i. Staining was also seen in the 
abdominal regions at 1 and 6 h p.i., likely due to the accumulation of HEVNPs in the liver or other organs 
prior to degradation (B). Modified from Chen et al., 2016.
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or associated with the liver, gallbladder, and pancreas through various ducts, 
veins, and arteries. Following ingestion of HEV, the virus capsid will be exposed 
to extreme conditions including highly acidic and then alkaline pH, a wide range 
of digestive enzymes, bile, bacteria and other microorganisms, thick mucosal 
layers, and mucosal flow throughout the 5-plus-meter length of the human 
digestive tract. At the cellular level, the inner surface of the intestines is lined 
with a layer of several types of simple columnar cells including villi and goblet 
cells that face the lumen. The villi and goblet cells are primarily involved in the 
absorption of digested nutrients and secretion of a thick (ca. 200 μm) layer of 
mucosa composed primarily of mucin, respectively. Microfold cells (M cells) 
are also found in the intestines which play important roles in the initiation of 
mucosal immunity and the transport of antigens across the epithelial cell layer. 
HEV has evolved to efficiently overcome these barriers (chemical, enzymatic, 
mechanical, physical, immunological, etc.) and to eventually initiate a produc-
tive infection of cells of the liver and other tissues. Although HEVNP is unable 
to replicate, it retains the inherent ability of HEV to efficiently target and 
deliver therapeutic agents through the GI tract with little or no toxicity [1, 2]. 
This ability of HEVNP to deliver, through oral dosing, a therapeutic payload in a 
targeted manner using a modular format is currently unavailable through other 
nanocarrier platforms. Additionally, HEVNP is highly stable to long-term stor-
age at room temperature. Thus, the need for a temperature-controlled supply 
chain for storage and distribution of HEVNP is minimized or eliminated. This 
makes the storage and distribution of HEVNP significantly less difficult espe-
cially in less developed regions. In addition to being stable at room temperature, 
HEVNP is water soluble and can be formulated as a liquid (as well as a cream, 
powder, or solid) which allows HEVNP to be administered noninvasively as a 
drink or droplet.
3.3 Significant payload capacity
HEVNP functions as an epitope nanocarrier through display of the epitope 
on its surface. HEVNP also has a large hollow core with a width that ranges from 
approximately 10 to 12 nm (Figure 3A) that can be loaded with a payload such as a 
nucleic acid chain, peptide, or small molecule. This large hollow core results from 
the space within HEVNP that in HEV encapsulates genomic RNA. A payload can be 
encapsulated within the hollow core of HEVNP using a simple process that revers-
ibly disassembles HEVNP and then reassembles it in the presence of the payload 
molecules. This reversible process occurs through chemical reduction, chelation of 
Ca2+, and the subsequent return of Ca2+ (Figure 3B). Specifically, HEVNP disas-
sembles in the presence of DTT and EGTA and reassembles by the slow addition of 
Ca2+. If peptide molecules such as insulin or inorganic molecules such as ferrite are 
present during the reassembly process, these molecules are encapsulated within the 
reassembled HEVNP. Similarly, in the presence of DNA or RNA, the reassembled 
HEVNP will incorporate the nucleic acid molecule, and HEVNP can function as an 
orally deliverable DNA vaccine nanocarrier (reviewed in [2]). For example, plasmid 
DNA-encoding HIV envelope gp120 has been encapsulated by HEV VLP, and this 
construct has been used to orally deliver the plasmid to the spleen, Peyer’s patches, 
and mesenteric lymph nodes of mice [33]. Cell-mediated immune (specific cyto-
toxic T-lymphocyte (CTL) response) and specific humoral responses are generated 
locally and systemically. A payload is not essential for HEVNP capsid formation or 
capsid stability, but having this capacity offers a way to further increase the epitope 
signal beyond the 60 epitope copies that can be placed through chemical conjuga-
tion or genetic insertion on the HEVNP surface via the P domains.
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3.4 Platform sustainability by prevention of self-immunity
While HEVNP exhibits natural tolerance against the harsh enzymatic envi-
ronment associated with the digestive tract, its repeated use as a drug delivery 
vehicle will quickly result in self-immunity if a mechanism is not in place to 
avoid this common problem. As discussed above, insertion of the HIV-1 P18 
peptide onto the surface P domain maintains the icosahedral arrangement of 
P18-HEVNP and indicates that intermolecular forces between the truncated 
CP of the recombinant nucleocapsid are not disrupted by the insertion of P18. 
Additionally, since the antigenicity of HEVNP lies specifically within the P 
domain, the insertion of the P18 peptide significantly lowers immune detection 
of the HEVNP vehicle [21] (Figure 4A). The immune reactivity of P18-HEVNP 
has been tested by two antibodies, 447-52D and HEP224. Antibody 447-52D 
specifically targets the V3 loop of HIV-1 gp120, and monoclonal antibody 
HEP224 targets the conformational epitope (i.e., the three loops around Y485) 
of the P domain of HEV CP. Based on ELISA experiments, antibody 447-52D 
shows preferential binding of P18-HEVNP. On the other hand, the binding 
of antibody HEP224 to the conformational epitope of the P domain of HEV 
CP is disrupted by the insertion of HIV P18 without altering the structural 
characteristic of HEVNP. Thus, insertion of specific peptides into the exposed 
P domain serves as a practical strategy to escape antibody recognition by the 
immune system (i.e., issues with self-immunity) while triggering the desired 
humoral and cellular responses against the attached/inserted antigen. Similarly, 
an HEV-specific monoclonal antibody, Fab230, fails to recognize HEVNP after 
maleimide-biotin conjugation at position N573C of HEVNP [30] (Figure 4B).  
Additionally, the geometrical constraints provided by the M domain provide a 
Figure 3. 
Structure and disassembly/reassembly of HEVNP. The HEVNP monomer is composed of three domains: Shell 
(S), middle (M), and protrusion (P). The surface and interior localization of these domains is indicated by 
the color map (A). A large hollow core is found in the interior of HEVNP (right image in A). The hollow core 
can encapsulate various payloads such as nucleic acids, peptides, small proteins, or small molecules. Electron 
microscopic images of the process of HEVNP disassembly (following the addition of EGTA and DTT) and 
reassembly following the addition of calcium (B).
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physical barrier for antibody binding which helps HEVNP avoid immune system 
surveillance by HEV-specific antibodies. These findings show the sustainability 
of the HEVNP nanocarrier platform.
3.5 Safety of HEVNP
HEV annually causes acute and self-limiting infection in about 20 million people 
worldwide [34–36]. The majority of people infected with HEV show clinical symp-
toms that are relatively mild, and death rates from hepatitis E are low. The disease, 
however, is more severe in pregnant women, and chronic infection may occur in 
immunocompromised individuals. Although the exact mechanism of the increased 
severity of the disease during pregnancy is unknown, there is some evidence that 
increased viral replication in placental tissues plays a role [34, 35]. Thus, in a large 
proportion of the population, HEV is naturally a low-virulence pathogen. The low 
virulence of HEV and the inability of HEVNP to replicate (because it does not carry 
HEV genomic RNA) suggest that an HEVNP-based nanocarrier will not induce 
undue virulence in patients.
3.6 Established production and engineering technology
A common eukaryotic cell-based technology for vaccine production utilizes 
recombinant baculoviruses and insect cells. Baculoviruses are arthropod-spe-
cific viruses that are commonly used to produce recombinant proteins for basic 
research and commercial applications. Baculoviruses have been successfully 
used to produce human therapeutics and diagnostics since the late 1990s [12]. 
A recent example of a baculovirus-based vaccine is Flublok (released in 2013 by 
Protein Sciences Corporation), a vaccine against human influenza virus. The 
baculovirus expression vector system is also used to express the major capsid 
protein L1 of human papilloma virus. The recombinant L1 capsid protein forms 
a VLP-based vaccine (Cervarix™) that protects against cervical cancer [12, 37]. 
The commercial GMP technology that is currently used to express and purify 
these vaccines and others can be easily adapted for the production of recom-
binant truncated CP and the engineering of HEVNP-based vaccine delivery 
nanocarriers.
Figure 4. 
3-D modeling of HEVNP surface modulation. Surface modulation through chemical conjugation or genetic 
modification promotes the escape of HEVNP from immune surveillance (A). Surface modulation of HEVNP 
with maleimide-biotin or mutation of the P domain at residue N573 dramatically reduces cross reactivity with 
the HEV-specific monoclonal antibody fab230 by ELISA (B).
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4. Single epitope modification of HEVNP: HIV-1 GP120 P18 example
As discussed earlier, insertion of the P18 peptide from the GP120 protein of 
HIV-1 results in a stable HEVNP that displays P18 on its surface (in the P domain 
after residue Y485). Additionally, the P18 insertion significantly lowers the immune 
system response against HEVNP. When the P18-HEVNP construct is orally 
inoculated into mice, it induces strong and specific cell-mediated and humoral 
responses in comparison to immunization with HEVNP [21]. After three rounds 
of oral immunization, the cell-mediated response includes the lysis of cytotoxic 
T lymphocytes (CTLs) in three immune system-associated organs. Similarly, 
humoral responses (IgG, IgA, and IgM induction) in the sera and intestinal fluids 
are detected by ELISA. These responses were generated by P18-HEVNP without the 
need for an external adjuvant coadministration.
5. Multiple epitope modifications of HEVNP: MOMP example
Over 120 million people are annually infected with Chlamydia trachomatis. 
Because the initial stages of chlamydia are generally asymptomatic, many individuals 
are unaware that they are infected and do not seek antibiotic treatment. As the infec-
tion spreads, chronic abdominal pain, pelvic inflammatory disease, ectopic preg-
nancy, and infertility can result. The major outer membrane protein (MOMP) of 
Chlamydia, in its native trimeric form (nMOMP), has been demonstrated to impart 
significant protection against chlamydial infection and disease in a mouse model. 
MOMP is a structurally rigid, 40 kDa trimer-forming protein that makes up about 
60% of the total mass of the outer membrane of Chlamydia [38, 39]. MOMP itself 
is characterized by five constant domains (CDs) and four variable domains (VDs) 
which help to define the immunogenicity of various serovars of Chlamydia [40, 41].
MOMP is the immunodominant antigen of Chlamydia and has multiple epitopes 
for T-cell and B-cell activation; thus, it induces both cell-mediated and humoral 
immunity [42–46]. Mice that are vaccinated with the nMOMP with Freund’s adju-
vant are significantly protected from the effects of Chlamydia in terms of a shed-
ding assay and infertility [47]. In contrast, denatured MOMP does not offer this 
protection. The denatured MOMP, however, induces a greater humoral response 
than nMOMP. Robust protective activity following vaccination with nMOMP and 
other adjuvants has also been reported [45, 48]; this activity was similar to that 
of mice that were immunized intranasally with live Chlamydia elementary bodies 
(EBs). These and other studies [47, 49–52] using various readouts (i.e., body weight, 
lung weight, number of inclusions forming units recovered, length of shedding, 
etc.) demonstrate the important role of MOMP in inducing protection against 
Chlamydia.
Formulating a vaccine with a properly folded membrane protein such as MOMP 
remains a genetic engineering challenge. The use of membrane proteins for vaccine 
applications requires a platform that can be engineered to enable proper folding of the 
membrane protein, potentially allow for adjuvant incorporation, and be amenable 
to the display of multiple epitopes employing multiple display strategies. In the past 
10 years, incorporating membrane proteins into nanolipoprotein particles for both 
solubility and stabilization has become increasingly common with varied success.
In our laboratory, HEVNP has been used as a platform to display two MOMP 
VD epitope sequences (VD1 and VD4). With this construct, HEVNP-VD1/
HEVNP-VD4, the VD1 and VD4 peptide sequences were genetically incorporated at 
S533 and T485, respectively, of the truncated capsid protein, a region corresponding 
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to surface-exposed loops L2 and L1, respectively. Analysis of the visibility of these 
epitopes by structural modeling (Figure 5) and by ELISA using VD1- or VD4-
specific antibodies (data not shown) indicates that all three of these constructs are 
highly immunogenic, suggesting that the epitopes are authentically displayed on the 
surface of HEVNP. Furthermore, in preliminary animal experiments, anti-MOMP 
IgG levels in the serum of mice that are immunized by HEVNP-VD1/HEVNP-VD4 
(prime and two boosts) are like those found following immunization with a whole 
Chlamydia cell vaccine. These findings are highly exciting; and we are currently 
investigating whether there is also a cell-mediated immune response induced by 
HEVNP-VD1/HEVNP-VD4 and, if there is, how this response compares with that 
induced by a whole cell vaccine.
6. Conclusions
As a nanocarrier, HEVNP is a structure that can display multiple epitopes on 
its surface; and simultaneously it can deliver a payload, for example, an epitope 
encoding nucleotide sequence, peptide, or small molecule. Unlike nanoparticles 
generated from polymers, lipids, nanotubes, or other carriers, HEVNP delivers 
epitopes and payload through the mucosa of the GI tract without the need for any, 
potentially deleterious, exogenous enhancers such as a mucosal breakdown enzyme, 
pH regulator, or uptake cofactor. The key characteristics that make HEVNP an 
ideal and unique vehicle for vaccine delivery include: (i) Surface plasticity. Sites 
on the P domain can be engineered for site-specific attachment or insertion of the 
epitope(s). Even when the surface of HEVNP is genetically or chemically modi-
fied, the core structure of HEVNP remains intact. (ii) GI tract stability. Even when 
surface modified, HEVNP is stable to the harsh conditions of low pH and proteo-
lytic enzymes that are found in the GI tract. This allows HEVNP to deliver epitopes 
orally. HEVNP has the capability to penetrate the mucosal lining of the entire GI 
tract and other mucosa-lined cavities or organs and directly target cells of the base-
ment membrane. (iii) Significant payload capacity. The large hollow core of HEVNP 
can package and protect large biological molecules including DNA and RNA. 
(iv) Platform sustainability. Immune recognition of the carrier platform is negated 
with HEVNP. The surface P domain carries the primary antigenic sites of HEV (and 
HEVNP). Thus, modification of the P domain by chemical conjugation or genetic 
insertion of a vaccine epitope completely neutralizes endogenous immunogenicity 
Figure 5. 
Chlamydial vaccine design. Peptide sequences from variable domain 1 (VD1, yellow epitopes) and/or VD4 
(orange epitopes) from the major outer membrane protein of Chlamydia were chemically conjugated to amino 
acid residue N573C (left and center panels) or genetically inserted (after amino acid residues S533 and T485, 
respectively, right panel) to the P domain of HEVNP.
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against HEVNP carrier platform. In addition, the HEVNP nanocarrier platform can 
overcome many of the drawbacks of other nanocarrier platforms including issues 
with (1) formulation, (2) production, (3) safety, (4) cold chain distribution, (5) 
target selectivity, and (6) signal amplification.
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